S242: EARLY INFUSION OF MSCS IN THE PROPHYLAXIS OF GVHD AFTER HAPLO-HEMATOPOIETIC STEM-CELL TRANSPLANTATION

S242: EARLY INFUSION OF MSCS IN THE PROPHYLAXIS OF GVHD AFTER HAPLO-HEMATOPOIETIC STEM-CELL TRANSPLANTATION

Bibliographic Details
Main Authors:	R. Huang, T. Chen, S. Wang, J. Wang, Y. Su, J. Liu, Q. Wen, P. Kong, C. Zhang, L. Gao, X. Zhang
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843860.51750.54

Similar Items

Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT
by: Rongmu Luo, et al.
Published: (2022-12-01)

The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety
by: Xiaoli Chen, et al.
Published: (2021-09-01)

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion
by: Ling Qi, et al.
Published: (2021-12-01)

GVHD Prophylaxis 2020
by: Mahasweta Gooptu, et al.
Published: (2021-04-01)

Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation
by: Lidan Zhu, et al.
Published: (2022-05-01)

P1396: EFFICACY AND SAFETY COMPARISON OF CALCINEURIN INHIBITORS USED FOR GVHD PROPHYLAXIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA
by: S. Zhumatayev, et al.
Published: (2022-06-01)

P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
by: F. Dachy, et al.
Published: (2022-06-01)

Bone marrow GvHD after allogeneic hematopoietic stem cell transplantation
by: Martin eSzyska, et al.
Published: (2016-03-01)

Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?—a systematic review and meta-analysis
by: Ruonan Li, et al.
Published: (2021-02-01)

P1324: EFFICACY AND SAFETY OF DOSE-ADJUSTED ATG COMBINED WITH CD25 ANTIBODY IN THE PREVENTION OF GVHD AFTER HAPLO-HSCT: CLINICAL STUDY DATA FROM A SINGLE CENTER IN CHINA
by: Lidan Zhu, et al.
Published: (2023-08-01)

PB2338: QUALITY OF LIFE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT OF CHRONIC GVHD
by: D. Belloumi, et al.
Published: (2022-06-01)

Bacterial Pathogens Causing Pneumonia Post Hematopoietic Stem Cell Transplant: The Chronic GVHD Population
by: Said Chaaban, et al.
Published: (2023-05-01)

P364: DONOR-DERIVED CD19 CAR-T CELLS AND CHEMOTHERAPY PLUS DONOR LYMPHOCYTE INFUSION IN THE TREATMENT OF RECURRENT CD19+ B-ALL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
by: X. Tan, et al.
Published: (2022-06-01)

Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
by: Binglei Zhang, et al.
Published: (2021-04-01)

Donor bone marrow-derived T cells inhibit GVHD induced by donor lymphocyte infusion in established mixed allogeneic hematopoietic chimeras.
by: Hui Wang, et al.
Published: (2012-01-01)

The role of animal models in the study of hematopoietic stem cell transplantation and GvHD: A historical overview.
by: Margherita Boieri, et al.
Published: (2016-08-01)

Donor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
by: Ryo Hanaki, et al.
Published: (2021-12-01)

P1341: HAPLO-CORD VS HAPLOIDENTICAL TRANSPLANT IN 49 CHILDREN – A RETROSPECTIVE SINGLE CENTER ANALYSIS
by: P. Fu, et al.
Published: (2022-06-01)

Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation
by: Guan Xiuqin, et al.
Published: (2009-04-01)

Comparison of HCMV DNA load and antigenemia results in hematopoietic transplant recipients based on GVHD grade
by: Pajand O, et al.
Published: (2007-05-01)

Galectin‐9 alleviates acute graft‐versus‐host disease after haplo‐hematopoietic stem cell transplantation by regulating regulatory T cell/effector T cell imbalance
by: Nannan Pang, et al.
Published: (2024-02-01)

The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD following Hematopoietic Stem Cell Transplantation
by: Seyed Asadollah Mousavi, et al.
Published: (2016-12-01)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
by: Yuan Song, et al.
Published: (2020-10-01)

Case Series Using Salvage Haplo-Identical Stem Cells for Secondary Transplantation
by: Alexandra Ionete, et al.
Published: (2023-06-01)

Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid Malignancies: A Single Arm Phase II Study
by: Jie-ling Jiang, et al.
Published: (2021-03-01)

IL-10 mRNA Engineered MSCs Demonstrate Enhanced Anti-Inflammation in an Acute GvHD Model
by: Cuiping Zhang, et al.
Published: (2021-11-01)

Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies
by: Lan Wang, et al.
Published: (2022-12-01)

Longitudinal Tear Protein Changes Correlate with Ocular Chronic GVHD Development in Allogeneic Hematopoietic Stem Cell Transplant Patients
by: Carmen Ciavarella, et al.
Published: (2021-09-01)

Pretransplant immunosuppression preceding haplo- identical transplant in children with thalassemia major
by: Shweta Pathak, et al.
Published: (2022-01-01)

HaploChIP: an in vivo assay.
by: Charles Knight, J
Published: (2005)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
by: Elizabeth A de Kort, et al.
Published: (2019-01-01)

Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation
by: Hemn Mohammadpour, et al.
Published: (2023-03-01)

Centromeric KIR AA Individuals Harbor Particular KIR Alleles Conferring Beneficial NK Cell Features with Implications in Haplo-Identical Hematopoietic Stem Cell Transplantation
by: Léa Dubreuil, et al.
Published: (2020-12-01)

The influence of methotrexate-related transporter and metabolizing enzyme gene polymorphisms on peri-engraftment syndrome and graft-versus-host disease after haplo-hematopoietic stem cell transplantation in pediatric patients with malignant hematological diseases
by: Qi Ji, et al.
Published: (2023-09-01)

The predictive value of stimulation index calculated by modified mixed lymphocyte culture in the detection of GVHD following hematopoietic stem cell transplantation
by: Hülya Sayılan Şen, et al.
Published: (2010-12-01)

The predictive value of stimulation index calculated by modified mixed lymphocyte culture in the detection of GVHD following hematopoietic stem cell transplantation
by: Hülya Sayılan Şen, et al.
Published: (2010-12-01)

Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning
by: R. S. Germeraad, et al.
Published: (2022-08-01)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
by: Jinye Zhu, et al.
Published: (2023-10-01)

UNRELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH CLASS I ANTIGENIC MISMATCH WITH IN VIVO POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) FOR GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: PROMISING STRATEGY TO TRANSPLANT PATIENTS WITH NON-MALIGNANT GENETIC DISEASES
by: CMMSS Parrode, et al.
Published: (2023-10-01)

Is It Better to Mobilize Hematopoietic Stem Cells With Pegfilgrastim in Healthy Donors During Allogeneic Hematopoietic Stem Cell Transplantation?
by: Jiali Li, et al.
Published: (2020-09-01)